NASDAQ:ARIA - Ariad Pharmaceuticals Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $23.99 0.00 (0.00 %) (As of 09/25/2018 03:06 AM ET)Previous Close$23.99Today's Range$23.99 - $23.9952-Week Range$4.67 - $23.99VolumeN/AAverage Volume15.70 million shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/ABetaN/A Company ProfileDiscussionAnalyst RatingsChartEarnings HistoryFinancialsInsider TradesHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email ARIAD Pharmaceuticals, Inc. (ARIAD) is an oncology company. The Company is focused on transforming the lives of cancer patients with medicines. The Company's product pipeline includes Iclusig (ponatinib), brigatinib, AP32788 and ridaforolimus. The Company's Iclusig is a tyrosine kinase inhibitor (TKI) that is approved in the United States, the European Union, Australia, Switzerland, Israel and Canada for the treatment of adult patients with chronic myeloid leukemia (CML), and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Its Brigatinib is an investigational inhibitor of anaplastic lymphoma kinase (ALK). Its AP32788 is a TKI, which is designed as a targeted therapy for patients with non-small cell lung cancer (NSCLC) with specific mutations in two kinases, epidermal growth factor receptor (EGFR), or human epidermal growth factor receptor 2 (HER2). Its Ridaforolimus is an investigational inhibitor of the mammalian target of rapamycin (mTOR). Receive ARIA News and Ratings via Email Sign-up to receive the latest news and ratings for ARIA and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry N/A Sub-IndustryBiotechnology SectorN/A SymbolNASDAQ:ARIA CUSIP04033A10 Webwww.ariad.com Phone+1-617-4940400 Debt Debt-to-Equity Ratio-11.28 Current Ratio3.17 Quick Ratio3.15 Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / CashN/A Book ValueN/A Price / BookN/A Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net Margins-60.47% Return on EquityN/A Return on Assets-17.16% Miscellaneous Employees459 Outstanding Shares194,390,000Market Cap$0.00 Ariad Pharmaceuticals (NASDAQ:ARIA) Frequently Asked Questions What is Ariad Pharmaceuticals' stock symbol? Ariad Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARIA." How were Ariad Pharmaceuticals' earnings last quarter? Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) released its quarterly earnings results on Thursday, July, 28th. The pharmaceutical company reported $0.59 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.11) by $0.70. The pharmaceutical company had revenue of $65.30 million for the quarter, compared to the consensus estimate of $60.64 million. The business's revenue was up 133.0% compared to the same quarter last year. During the same quarter last year, the company posted ($0.28) EPS. View Ariad Pharmaceuticals' Earnings History. How do I buy shares of Ariad Pharmaceuticals? Shares of ARIA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Ariad Pharmaceuticals' stock price today? One share of ARIA stock can currently be purchased for approximately $23.99. What is Ariad Pharmaceuticals' official website? The official website for Ariad Pharmaceuticals is http://www.ariad.com. How can I contact Ariad Pharmaceuticals? Ariad Pharmaceuticals' mailing address is 125 Binney St, CAMBRIDGE, MA 02142-1123, United States. The pharmaceutical company can be reached via phone at +1-617-4940400. MarketBeat Community Rating for Ariad Pharmaceuticals (NASDAQ ARIA)Community Ranking: 2.9 out of 5 ( )Outperform Votes: 485 (Vote Outperform)Underperform Votes: 359 (Vote Underperform)Total Votes: 844MarketBeat's community ratings are surveys of what our community members think about Ariad Pharmaceuticals and other stocks. Vote "Outperform" if you believe ARIA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARIA will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 9/25/2018 by MarketBeat.com StaffFeatured Article: What does the Dow Jones Industrial Average (DJIA) measure?